Monday, June 1, 2015

Opto Circuits posts Rs. 286.52 crs in Consolidated Sales for Q4FY15, Net Profit of Rs. 8.32 crs

India | June 1, 2015:

Opto Circuits (India) Ltd. (Bloomberg: OPTCIN; Reuters: OPTO.NS; NSE: OPTOCIRCUI; BSE: 532391) announced audited financial results for the fourth quarter and full year ending March 31st, 2015.

The consolidated sales for the quarter ended 31st March 2015, was Rs. 286.52 crs registering a growth of 3% in comparison to corresponding quarter of the previous year of Rs. 278.33 crs. The consolidated profit increased by 214% to Rs. 8.32 crs compared to Rs. 2.65 crs in the corresponding quarter of the previous year.

The consolidated sales for the whole year ended 31st March 2015, was Rs. 1,186.79 crs whereas consolidated loss stood at Rs. 146.96 crs. For the whole year ended 31st March 2015, the medical equipment (Non- invasive) contribution to consolidated sales was 90% whereas the interventional devices (invasive) contribution was 9.5%.

Note on extraordinary item for FY15

In Q3FY15, the company’s factory and facility at Vishakhapatnam, Andhra Pradesh incurred losses of inventory and machinery on account of Hud Hud cyclone.  Following a conservative approach as per accounting conventions, the company provided for loss of inventory in the said quarter. 

Commenting on the performance, Mr. Vinod Ramnani, Chairman and Managing Director, Opto Circuits India said, “I believe that we our recently approved cardiac resuscitation AED product and our Sirolimus coated Drug-eluting stent have helped strengthen our product offering which will accelerate the growth momentum in the coming years.

“For the year ended March 31st, 2015 our consolidated profit was Rs. 34 crs. As explained above, we charged to profit and loss statement Rs. 181 crs incurred due to loss of inventory and damages to our factory on account of the Hud Hud cyclone.”

About Opto Circuits (India) Limited

Opto Circuits (India) Ltd. (OCI) is a vertically integrated multinational medical technology group that specializes in primary, acute and critical care products for the global markets. Group companies such as Cardiac Science, Criticare, Eurocor, Mediaid, AMDL and Unetixs Vascular are leaders in vital signs monitors, emergency cardiac care equipment, vascular treatments and sensing technologies. Our USFDA listed and CE marked products are marketed in more than 150 countries and sold through direct and indirect sales channels across many emerging and developed economies. We’ve been ranked in Forbes’ Asia’s 200 Best under a Billion lists in 2008, 2009 and 2011. For more information, please visit

No comments:

Post a Comment